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Abstract
Background: Oxygen therapy is recommended for all of the 1.5 – 2.7 million young children who consult health
services with hypoxemic pneumonia each year, and the many more with other serious conditions. However,
oxygen supplies are intermittent throughout the developing world. Although oxygen is well established as a
treatment for hypoxemic pneumonia, quantitative evidence for its effect is lacking. This review aims to assess the
utility of oxygen systems as a method for reducing childhood mortality from pneumonia.
Methods: Aiming to improve priority setting methods, The Child Health and Nutrition Research Initiative (CHNRI)
has developed a common framework to score competing interventions into child health. That framework involves
the assessment of 12 different criteria upon which interventions can be compared. This report follows the
proposed framework, using a semi-systematic literature review and the results of a structured exercise gathering
opinion from experts (leading basic scientists, international public health researchers, international policy makers
and representatives of pharmaceutical companies), to assess and score each criterion as their “collective optimism”
towards each, on a scale from 0 to 100%.
Results: A rough estimate from an analysis of the literature suggests that global strengthening of oxygen systems
could save lives of up to 122,000 children from pneumonia annually. Following 12 CHNRI criteria, the experts expressed
very high levels of optimism (over 80%) for answerability, low development cost and low product cost; high levels of
optimism (60-80%) for low implementation cost, likelihood of efficacy, deliverability, acceptance to end users and health
workers; and moderate levels of optimism (40-60%) for impact on equity, affordability and sustainability. The median
estimate of potential effectiveness of oxygen systems to reduce the overall childhood pneumonia mortality was ~20%
(interquartile range: 10-35%, min. 0%, max. 50%). However, problems with oxygen systems in terms of affordability,
sustainability and impact on equity are noted in both expert opinion scores and on review.
Conclusion: Oxygen systems are likely to be an effective intervention in combating childhood mortality from
pneumonia. However, a number of gaps in the evidence base exist that should be addressed to complete the
investment case and research addressing these issues merit greater funding attention.
Background
The fourth Millennium Development Goal laid out
ambitious targets for reducing childhood mortality
among children under five by two thirds, by 2015 [1].
Because it is the leading cause of child deaths in the
world, combating pneumonia should be central to stra-
tegies for reducing childhood mortality [2-4].
Several pathophysiological mechanisms cause death
from pneumonia, but sepsis and hypoxemia are the two
key mechanisms. A recent review estimated the preva-
lence of hypoxemic pneumonia amongst young children
presenting to health services each year at 1.5 to 2.7 mil-
lion [5]. Although all of these children would benefit
from treatment with supplemental oxygen [6], supplies
are often unavailable and inappropriately utilised
throughout the developing world [7-9]. It has been
argued that introducing robust oxygen systems with
well-trained and equipped staff could substantially
reduce mortality from pneumonia [10].
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international health, The Child Health and Nutrition
Research Initiative (CHNRI) has developed a common
framework to score interventions that aim to reduce dis-
ease burden [11-15] and implemented this methodology
for research prioritization in a wide range of contexts
[16-20]. This paper aims to use this framework in order
to assess oxygen systems as a method for reducing pae-
diatric mortality from pneumonia and to enable the
comparison of oxygen systems to other relevant inter-
ventions (see also other publications in this series).
Methods
F o rt h i sp r o j e c t ,at w os t a g eC H N R If r a m e w o r kw a s
used to assess the utility of oxygen systems. The first
stage involved a thorough literature review of predefined
criteria for scoring interventions against childhood
pneumonia, laid out by CHNRI [11-15]. Criteria were
chosen to best reflect the key elements of any interven-
tion that should be taken into account for priority set-
ting and included: (i) answerability, (ii) cost of
development, (iii) cost of product, (iv) cost of implemen-
tation, (v) efficacy and effectiveness, (vi) deliverability,
(vii) affordability, (viii) sustainability, (ix) maximum
potential for disease burden reduction, (x) acceptability
to health workers, (xi9 acceptability to end users, and
(xii) effect on equity. An illustration of the format of
this approach is outlined in Figure 1.
The second stage of the framework involved an expert
opinion analysis, which made use of the opinions of 20
experts in relevant fields and included five basic scien-
tists, five public health researchers, five international
policy makers and five pharmaceutical representatives.
Of these representatives, those involved in policy and
pharmaceuticals participated on the condition of anon-
ymity, because of highly sensitive nature of their invol-
vement in similar exercises.
CHNRI exercise – stage I: Identification and selection of
studies
A literature search was performed for articles relating to
oxygen therapy for paediatric hospital care in the devel-
oping world between 1950 and 2009. Using relevant
keywords, we searched the databases of Pubmed,
Pubmed Central, The Cochrane Library and those of
developing countries including: LILACS - the Latin
American and Caribbean Health Sciences Literature
database, and IndMed - the Indian biomedical database.
Titles and abstracts were reviewed for relevance. The
references of relevant articles were screened to identify
further useful articles.
A total of 315 articles were retrieved from PubMed,
8 6 2f r o mP u b m e dC e n t r a l ,2 2f r o mt h eC o c h r a n e
Library, 3 from IndMed and none from LILACS. After
review of the titles of all articles and the references of
those deemed useful, 96 full texts were located for inclu-
sion in the study. Guidelines for oxygen use in develop-
ing countries were also located from the WHO website,
and articles were taken from the International Union
Against Tuberculosis and Lung Diseases. Details of the
search and inclusion and exclusion criteria can be found
in the Supplementary Table S1 in Additional File 1.
For sections covering Answerability and Efficacy, a
separate search was conducted using relevant keywords,
up to 2009. Historical accounts were useful, as only 8
journal articles were found to be of relevance. This is
due to the early uptake of oxygen into medical practice
discussed in the following sections. These historical
accounts included internet resources and the WHO
handbook (1993) [21].
CHNRI exercise – stage II: An expert opinion exercise
To conduct the CHNRI expert opinion exercise, a preli-
minary review of the literature was provided and pre-
sented to the 20 experts that participated in a one week
meeting held in Dubrovnik, Croatia, on September 7-13,
2009. The views of the experts were collected using a
questionnaire designed to capture the opinion on all
CHNRI criteria (Supplementary Table S2 in Additional
File 1). The list of chosen experts included five leading
basic scientists, five international public health research-
ers, five international policy makers and five representa-
tives of the pharmaceutical companies.
The 20 experts were chosen based on their excel-
lent track record in child health research, particularly
childhood pneumonia. We initially offered participa-
tion to the 20 experts with the greatest impact of
publications in their area of expertise over the past 5
years (for basic researchers and international public
health researchers), or for being affiliated to the lar-
gest pharmaceutical company in terms of vaccination
programme or international agency in terms of their
annual budget. For those who declined to participate
(4 experts - about 20% - mainly due to conflicting
arrangements/travel), replacements were found using
t h es a m ec r i t e r i a :f o rb a s ic scientists and public
health researchers we used Web of Knowledge and
“pneumonia or ALRI” as search subject and limited
time period to 2001-2008. This gave us a larger num-
ber of papers, which we sorted according to number
of citations received. Then, we went down the ranks
and invited the corresponding authors of the studies
that were most relevant to the topic of our expert
p a n e l .T h ep o l i c ym a k e r sa n dindustry representatives
accepted our invitation on the condition of anonym-
ity, due to sensitive nature of their involvement in
such exercises. About half of the experts were either
affiliated to institutions in developing countries or
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country settings.
The experts met during September 2009 to conduct
the 2nd stage of CHNRI expert opinion exercise. All
invited experts discussed the evidence provided in
C H N R Is t a g eI ,a n dt h e na n s w e r e dq u e s t i o n sf r o m
CHNRI framework Supplementary Table S2 in Addi-
tional File 1. Their answers could have been “Yes” (1
point), “No” (0 points), “N e i t h e rY e sn o rN o ” (0.5
points) or “Don’tk n o w ” (blank). Their “collective
Figure 1 An illustration of the format of CHNRI approach for scoring interventions against childhood pneumonia.
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scale from 0 to 100%. The interpretation of this metric
for each criterion is straightforward: it is calculated as
the number of points that each evaluated type of emer-
ging RSV vaccine received from 20 experts (based on
their responses to questions from CHNRI framework),
divided by the maximum possible number of points (if
all answers from all experts are “Yes”). This was carried
out for each question, dividing the sum of points
received by the maximum number of points that could
have been achieved. The exact computation methods
have been explained at length and presented elsewhere
[11-15]. An outline of the second stage of the CHNRI
format can be viewed in Figure 2.
Results
Answerability
Oxygen is a well established treatment for hypoxemic
pneumonia. It has been used in medical practice since
the end of the 18
th century, but it was placed on a firm
theoretical base for pneumonia by Haldane in the 1920s
[22]. His description of oxygen and carbon dioxide
Figure 2 A summary of Stage II of the CHNRI process of an evaluation of emerging intervention (an expert opinion exercise using the CHNRI
criteria).
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gen as the standard treatment of “anoxemia” [22,23].
Due to the early and enthusiastic uptake of this treat-
ment, empirical evidence for its benefit is virtually non
existent. Any fully randomised controlled trial to estab-
lish the efficacy of oxygen therapy would require the
withholding of oxygen from a control group, but once
the theoretical basis for oxygen was understood, with-
holding oxygen in this way immediately became
unethical.
Efficacy - The impact of the oxygen systems under ideal
conditions
No controlled trial has ever measured the therapeutic
impact of oxygen in humans directly, but it is possible
to estimate the effect in other ways. For example, mor-
tality rates from studies prior to the introduction of oxy-
g e nt h e r a p yc a nb ec o m p a r e dw i t ht h o s ea f t e r w a r d s
[21]. Due to the variability in severity between pneumo-
nia outbreaks, one must have an adequate indicator of
disease severity to be enable a meaningful comparison.
In some early studies, arterial oxygen saturations
were recorded without the administration of oxygen
therapy [24]. The outcomes of these patients can be
compared with those from a similar time period in
which oxygen saturations were taken and oxygen ther-
apy provided [21]. When adjusted for illness severity,
this comparison shows a mortality rate of 39%
amongst those treated with oxygen and 74% in those
without [21]. Although this suggests a significant
impact, the patient numbers in those studies were far
too small to provide statistical significance - in the
s t u d yo fS t a d i e( 1 9 1 9 )t h e r ew e r eo n l y3 4p a t i e n t si n
non-oxygen group [24]. Furthermore, these studies all
took place in the pre-antibiotic era (hence the very
high case fatality ratios) and so are of questionable
relevance to the situation today [25-28].
Studies on guinea pigs infected with streptococci sup-
port the benefit of oxygen therapy: for animals kept in
air mortality was 94%, while it was 49% for animals kept
in 50% oxygen [21]. This empirical evidence is insuffi-
cient to make estimates of efficacy for oxygen therapy,
but the current clinical consensus strongly, and subse-
quent studies support the efficacy of oxygen therapy.
There is a strong theoretical and experiential basis,
founded on decades of beneficial experiences of oxygen
therapy in clinical practice, such that it is now a univer-
sally accepted standard of care in the management of
hypoxaemia. The incorporation into most treatment
algorithms of severe pneumonia in the world through-
out the last century further establishes the benefit of
oxygen therapy [6,23,29,30]. Therefore, it can be safely
assumed that oxygen is an important part of treatment
in severe pneumonia.
Efficacy and effectiveness - The impact of oxygen systems
in the population
The effectiveness of an oxygen system depends upon
three stages in its delivery: the correct identification of
patients requiring treatment; an effective method of
administration; and adequate monitoring and eventual
discontinuation of the therapy.
Current WHO guidelines advise oxygen therapy for
every child with “very severe pneumonia” [6], which is
diagnosed when following signs are observed: cough or
difficult breathing, plus at least one of the following: (i)
central cyanosis, (ii) inability to breastfeed or drink (or
vomiting everything), (iii) convulsions, lethargy or
unconsciousness, or (iv) severe respiratory distress.
Numerous studies have been conducted into the sensi-
tivity and specificity of these clinical signs in the detec-
tion of hypoxemia [26,31-33] and wide variability has
been found in the reported accuracies. For example,
Dyke and colleagues found the sensitivity of chest in-
drawing to be 98% and its specificity to be just 7%,
whereas Gutierrez and colleagues found them to be 59%
and 63% respectively [32,34]. These figures do not
improve much when using multiple signs; although sen-
sitivity can be increased, it is often at the expense of
unacceptable specificity. Even the WHO treatment algo-
rithms can inappropriately treat up to 50% of patients
[31]. Indeed, a recent Cochrane review concluded that
“there is still no clinical sign, model or score system that
accurately identifies hypoxemic children”, a position that
seems valid on analysis of the evidence base [35]. In the
setting of such clinical uncertainty an adequate diagnos-
tic investigation is needed. The pulse oximeter repre-
sents such a device. However, very few hospitals in the
developing world have access to oximetry, despite per-
sistent calls for uptake [10,36-38].
Modes of oxygen delivery include nasal prongs, naso-
pharyngeal catheters, nasal catheters, facemasks and
head boxes [21]. The choice of method should be made
according to the situation, but in most hospitals and for
most children nasal prongs are recommended [21].
Nasal prongs demonstrate a similar therapeutic effect
and lower complication rates than other methods
[39,40]. Face masks and head boxes have high oxygen
requirements which outweigh their benefits in a low
resource setting [21,35,39,40].
With these three stages in mind, the true effectiveness
of an oxygen system can be adequately assessed only
through studies in which pulse oximetry was introduced,
an appropriate oxygen delivery system used and ade-
quately trained staff has diagnosed, monitored and dis-
continued therapy. To date, the only study that has
formally evaluated the effectiveness an oxygen system
whilst covering these three considerations was underta-
ken by Duke and colleagues in Papua New Guinea [10].
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compared from five hospitals before (2001-2004) and
after (2005-2007) the implementation of such a system.
They found that pneumonia mortality decreased by 35%
(p<0.0001) after the introduction of an improved oxygen
system. Although methodical issues can be raised over
the comparison of children from different time periods,
the confidence intervals supplied (48% - 22%) were still
highly significant. In addition to this there are reports of
observational studies describing large scale programmes
which have introduced an oxygen system and have
reported subsequent falls in pneumonia case fatality
ratios [41]. However, more research is needed to further
assess effectiveness in different contexts, and to evaluate
the potential for such systems to reach a national scale
in developing countries.
In this current exercise experts were highly optimistic
(78%) about the effectiveness of oxygen therapy inter-
ventions for the reduction of deaths from childhood
pneumonia Figure 3.
Deliverability and sustainability
An accurate assessment of the current state of oxygen
systems throughout the world would be invaluable for
estimating the delivery requirements of improving oxy-
gen capacity globally. Unfortunately, although research
reports and accessible governmental data are becoming
available on this topic there is still a need for further
well designed studies to identify the major problems and
suggest and evaluate appropriate strategies to tackle
these. In some instances broader research questions,
ranging from assessments of general hospital capacity to
maternity ward facilities, include details about oxygen
systems [7-9,42-44]. Although not all of these studies
contain much detail on oxygen specifically, information
can be extracted to aid understanding of the current
capacity.
Table 1 shows how deficiencies differ greatly between
regions. The countries of the former Soviet Union (e.g.
Moldova, Kazakhstan and Russian Federation) have
access to oxygen in between 72 and 95% of hospitals,
but this oxygen supply is primarily available in Intensive
Care Units rather than paediatric wards, and suffers
from extensive equipment shortages. In several Russian
hospitals oxygen was administered without flow meters
and fed through shower heads to neonates [7]. In the
Commonwealth of Independent States the primary
requirements would be strengthening current systems
with equipment and training [7].
On the other hand, more general deficiencies were
found in the African region. A study in Kenya found that
demand was outstripping supply in 11 out of 14 hospitals,
and none had an oximeter [8]. A Tanzanian survey
showed that 75% of hospitals had access to sufficient
oxygen in less than 25% of the time [42]. These problems
exist in some form or another throughout the developing
world. A study of 21 hospitals in 7 developing countries
ranging from Ethiopia to the Philippines showed that oxy-
gen was only available in the emergency treatment areas
of 47% of district hospitals [9]. Reports suggest that oxy-
gen supplies are now reaching even the most remote parts
of Africa, but sustainability is often prohibitive [45]. Over-
all, intermittent supplies, inadequate equipment and lack
of training can be found in almost every region of the
developing world [7,8,46,47].
In the past, a solution to this problem has been to
accept foreign donations of oxygen equipment, but this
has recently been demonstrated to be ineffective [48,49].
Without adequate training and maintenance, equipment
can quickly fall into disrepair [50]. Using the evidence
base it is possible to outline the equipment, infrastruc-
ture and funds that are necessary for implementing a
system in most countries. It should be remembered that
any planned upgrade of oxygen systems should be pre-
ceded by a review of a specific setting, current oxygen
supply and attitudes of health workers and end users.
Equipment
There are two main sources of oxygen in hospitals:
cylinders and concentrators. Oxygen cylinders contain
the gas in compressed form. The empty cylinders have
low capital costs (high cost when bought with flow-
meters [51]), do not require an electrical supply but
they need refilling at a supplier. The transport to the
supplier can sometimes be challenging and costly in
developing regions [45]. The gas itself is comparatively
expensive at $4.80 to $6.56 per 1000 litres [51].
Oxygen concentrators are machines which can con-
centrate oxygen (up to 90%) at the bedside, by the
absorption of nitrogen from atmospheric air. The pro-
duct gas can be connected to up to four patients
through flow splitters or a flow meter. Good quality
concentrators delivering 5-10 L/min currently cost
between $650 and $1500. They require an electricity
supply, but produce oxygen at a far cheaper rate than
cylinders. A study in Gambia estimated the cost per
1000 litres from concentrators at $0.84. This was calcu-
lated from a total cost in the period of 45 days when
only concentrators were to be used in Medical Research
Council Hospital, Fajara. The total cost comprised of
estimated proportional concentrator capital (projected
lifespan of 5 years) and running cost for this 45-day per-
iod, but it also included estimated proportional cylinder
capital (projected lifespan of 20 years) and running costs
in this period (because cylinders were used for 1 day,
d u et oa no v e r s i g h t )[ 5 1 ] .T h e yh a v es o m e t i m e sb e e n
seen to pay for themselves within 6 months of purchase
[52]. Concentrators have been tested in several regions
of the developing world from Egypt and Malawi to
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machines that fulfil both international standards (under
the International Organisation for Standardisation) have
been found most effective and durable when put to hard
use [48].
There are several concentrator models on the market
that are mostly appropriate for developing countries;
however official WHO/UNICEF specifications have not
yet been published [53,54].
For the reasons of cost and accessibility, many
researchers have advised the use of concentrators
[21,48,52]. However, although electricity is reaching ever
more remote regions of the world, it can be unreliable
[21,48,52]. A study in Malawi showed that cuts of
Oxygen delivery systems for low-resource settings
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Figure 3 The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in oxygen. For Max
Burden Reduction: Median (IQR): 20% (10, 35%), min: 0%, max: 50%.
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Howie (2009) developed an options assessment tool to
determine the most appropriate form of oxygen supply
in hospitals in Gambia [51]. Their analysis shows that if
the national grid was constant, concentrators were far
cheaper, showing an average annual facility cost of
$18,742, rather than $152,747 for delivering oxygen
using cylinders. However, electricity supplies were rarely
available for 20 hours per day and the additional cost of
stand-alone generators was not justifiable compared to
cylinders. They developed a decision making algorithm
based on their assessment tool, which stated that where
an electrical supply was feasible or transport links
unworkable, concentrators should be used; where elec-
tricity was unavailable but transport good, cylinders
were appropriate. During their analysis they found that
10 out of 12 government facilities would in fact be more
suited to cylinders than concentrators [51], but the
authors noted that transport links to Gambian hospitals
are generally good, which might not be true for other
developing countries. In addition, other studies have
shown transportation costs to reduce the sustainability
of cylinders [45]. The trade off between concentrators
and cylinders is complicated and decisions should be
made according to setting. Advances in technology may
eventually simplify this issue. Concentrators can be run
off solar power [55], and those that fill cylinders directly
are on the market [36]. However, this is currently very
expensive: $25,000 for the solar panel to power a $650
concentrator (personal correspondence). Although these
may not be appropriate in the developing world yet
[51], they could eventually solve the problem of inter-
mittent electricity. In addition, increasing access to elec-
tricity will favour the low cost oxygen of concentrators
in future.
All equipment for oxygen systems should be bought
with appropriate accessories and spares, such as nasal
prongs, for the expected period of use [48]. This will
increase the sustainability of the system as purchase of
new spares from abroad can be problematic [48]. In
addition, Matai (2008) has laid out guidance on selecting
and purchasing oximeters for developing nations [56].
New oximeters are also in development, some with
wind-up and solar power supplies specifically for use in
remote hospitals [57].
The overall deliverability of oxygen received a score of
only 0.64 in our expert opinion exercise reflecting the
fact that the achievement of a successful oxygen delivery
system nationwide is a complex and multidimensional
challenge. A key element of this is to ensure proper
ongoing maintenance of the system to maintain maxi-
mal function. This is why oxygen received a score of
only 0.54 (out of maximum 1.00) on expert opinion for
sustainability. Significant planning and infrastructure are
required for successful implementation of oxygen
systems.
Infrastructure
There have been several attempts to implement sustain-
able oxygen systems in developing regions, all using
concentrators [48,52,56]. The experiences of these
reports give valuable indications of the infrastructural
requirements of an oxygen system. The most consistent
observation is that prior to introduction, extensive train-
ing of staff is essential.
The day-to-day maintenance of concentrators is rela-
tively easy, but capacity for regular servicing and repair
must be available. Nursing and medical staff can be
trained to clean the filters and perform general mainte-
nance [21,56]. Minor malfunctions can often be repaired
by local engineers while electro-medical engineers
should be trained for major problems and visit every 4-6
months [21,48,52,56].
The comfort of health care workers in using such
technology is an important factor in usage [48,58].
Table 1 An availability of oxygen systems in different regions
Author Date Location Health setting Specific
Availability
Number of
facilities
Percent
with
oxygen
Supply
outstrips
demand
Kambarami 2000 Zimbabwe Primary Health
Care setting
Obstetric
care
13 23% n
Nolan 2001 Bangladesh, Dominican Republic, Ethiopia,
Indonesia, Philippines, Tanzania, Uganda
Teaching and
district hospitals
Paediatric
care
21 77-87% y
Simoes 2003 Uganda, Tanzania, Niger Primary care
facilities
Paediatric
care
62 5% y
English 2004 Kenya Outpatient clinic Paediatric
care
14 14% y
Wandi 2006 Papua New Guinea Hospitals Paediatric
care
5 - 22% of children
not treated
Duke 2006 Kazakhstan, Moldova, Russian Federation Hospitals Paediatric
care
17 72-95% y
Hill 2009 The Gambia Health facilities All areas 12 25% y
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tions, monitoring and discontinuation of oxygen therapy
and with oximetry [56]. In a region with high staff turn-
over, training should be updated regularly to retain
k n o w l e d g e .T h i sc a nb ed o n eb ya na n n u a lv i s i tf r o m
specialists at the central hospitals, or with the setting up
of a national “oxygen team” [48,56].
Cost of development and implementation and
affordability
Two studies have outlined the costs involved in imple-
menting a full, sustainable, oxygen system to paediatric
wards; both used concentrators. In the first study by
Enarson (2008), WHO approved concentrators were
supplied to 22 district hospitals and 3 regional hospitals
in Malawi [48]. In the second study in Papua New Gui-
nea, the National Health department supplied 15 con-
centrators to 5 provincial and district hospitals [10].
Although costs will vary according to setting and time, a
comparison of the expenditure of these two studies can
be useful (Table 2).
These studies show that with adequate planning, train-
ing and repairs, oxygen concentrators can be sustainably
implemented in district hospitals for an overall cost of
between $3670 and $6320 per unit. The funds are split
between equipment and human resources at roughly
55% vs. 45%, respectively. Both studies emphasise the
benefits of investing in human resources. The actual
cost of the concentrators was a low proportion of the
total and over the first 5 years – in the low maintenance
stage of a concentrators lifespan - becomes even less. In
our own investigation, the average price of a suitable 4-
litre concentrator was found to be between $650 and
$1000.
If a cylinder system were chosen, in the best-case sce-
nario the average annual cost to an average sized Gam-
bian paediatric ward with the minimal leakage would be
$5,000 per year [51]. This is compared to $1,500, in the
best-case scenario for concentrator system with 24
hours of electricity per day and a five year life-span.
Pulse oximeters varied greatly in price [59]. Although
very cheap models exist (<$100), those that have been
used effectively in developing countries were generally
more expensive [36,56]. The unit cost of an oximeter in
the study of Duke and colleagues came to $2280. In
addition, the disposable sensor probes were $217 each,
and 30 were required to maintain seven oximeters for
five years. Currently, suitable oximeters can be bought
with a 5 year supply of sensor probes for $2000, roughly
$10 per week of 5-year use [36]. A Global Pulse Oxime-
try Project has been launched which aims to encourage
the development and distribution of suitable oximeters
throughout the world (G.O. Project Report 2008). This
project estimated the demand in developing countries to
be over 100,000 units.
Cost effectiveness can be investigated by comparing
patient outcomes with costs. Overall, in Papua New
Guinea over 2.5 years in 5 hospitals 72 (CI: 52-94) chil-
dren were estimated to have survived who would have
otherwise died [10]. As the total cost of the project
came to $120,462, the cost per additional life saved was
$1673 (CI 1282-2317). If the Disability Adjusted Life
Expectancy in Papua New Guinea is estimated at 33
then the price per DALY is $50 [10]. This is a conserva-
tive estimate. Many concentrators will last more than 5
years, the equipment will be used on children who have
other hypoxemic conditions, and adjusted life expectan-
c i e sa r el i k e l yt or i s ei nt h ef u t u r e .T h ee x p e r tg r o u p
score of 1.0 for development cost reflects the fact that
this technology is already developed to a level that it is
ready for implementation and no further major develop-
ment costs are required (Figure 3).
Maximum potential for disease burden reduction
Estimating the potential reductions in disease burden
that oxygen systems could achieve is problematic given
the current evidence base. An attempt can be made but
the results should be treated with caution. A recent sys-
tematic review of 21 studies has estimated that between
1.5 and 2.7 million children consult health facilities with
hypoxemic pneumonia worldwide each year [5]. Accord-
ing to WHO guidelines, every one of these children
should receive oxygen therapy [21].
T h ed e a t hr a t ea m o n g s th y p o x e m i cp n e u m o n i a ,a s
opposed to pneumonia without hypoxemia, can be esti-
mated through analysis of studies measuring oxygen
saturations. If the 35% reduction in mortality found in
the Duke study could be replicated by improving oxygen
Table 2 A comparison of two studies for the costs of
oxygen systems
Item Enarson
(2008)
Duke
(2008)
Concentrators $850 $2520
Installation materials $1160 $830
Training and implementation $1230 $970
Other (review visits and electro-medical
repair)
$430 $2000
TOTAL (per unit) $3670 $6320
Items relating to oximetry:
Pulse oximeters and Oximetry sensor
probes
Not available $2280
TOTAL (per unit and including pulse
oximetry)
Not
available
$8600
Note: the cost of pulse oximeters and oximetry sensor probes was not estimated
in the study of Enarson et al. (2008). The oxygen system is not complete without
pulse oximetry.
*All costs are averages for each unit rounded to the nearest 10.
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Page 9 of 12systems in all regions, it could be expected to save
between 68,000 and 122,000 lives. Because only one
study was used to drive this global estimate, it should
only be used as a rough guide and generalisation should
be performed with caution before further evidence is
gathered.
During our expert opinion analysis, the median maxi-
mum disease burden reduction of oxygen systems
against childhood pneumonia was estimated at 20%,
interquartile range of 10-35% (Figure 3).
Acceptability and equity
Generally, oxygen is an acceptable intervention to both
health workers and end users. However, it should be
emphasised that the benefits of improving oxygen sys-
tems will only be felt by the 1.5 to 2.7 million children
who consult the health services. The most vulnerable
group in society, who are beyond the reach of the health
sector, will not benefit. For this reason the intervention
can be expected to reduce mortality from pneumonia
but may not improve levels of inequity. On the other
hand, it is also possible that through a strengthening of
capacity in health services, the intervention might bring
more of the population within reach of the health sec-
tor. Equally, falling case fatality rates and improved
quality of care may result in higher levels of health ser-
vices utilisation by all sectors of the population so the
overall impact on equity is uncertain. There is no
research on this subject and it is an area that would
benefit from further investigation. The expert analysis
demonstrated these doubts about the potential impact
of oxygen systems in reducing child health inequities
yielding a score of only 0.44, whereas the optimism over
acceptability to both health workers and end users was
high (60-80%) (Figure 3).
Discussion
Although methodologically imperfect, this report pro-
vides valuable insights into the utility of oxygen systems
and areas of uncertainty surrounding them. The limited
efficacy data for supplemental oxygen in pneumonia is
problematic, but addressed by decades of experience
throughout the world. More robust evidence for effec-
tiveness in different context and at a national scale is
needed if investment in the area is to occur. The com-
mon consensus and theoretical understanding attempt
to address this; however, multiple studies similar to
those in Papua New Guinea [10] but covering other
regions of the world would place oxygen systems on a
far firmer evidence base. If the 35% reduction in mortal-
ity found in this study could be replicated in other
regions, oxygen systems would appear much more likely
to have a significant part in combating pneumonia. The
highly conservative and rough estimates for mortality
reduction of between 68,000 and 122,000 lives are
encouragingly large.
Unlike other interventions such as antibiotics and vac-
cines, oxygen can be used to combat any form of
hypoxemic pneumonia, regardless of its aetiology. It
m a yb ea se f f e c t i v ea tt r e a t i n gt h ev a r i o u sp a t t e r n so f
acute respiratory diseases in neonates, as well as other
hypoxemic conditions found in children [5,60]. In addi-
tion, improved oxygen systems could have the added
benefit of strengthening existing health facilities [10].
The deliverability of oxygen systems has never been
more practical. Development of oxygen concentrators in
the 1960s combined with recent research into their
implementation in Malawi, Egypt and Papua New Gui-
nea have greatly advanced the potential for building sus-
tainable systems in regions with electricity. A systematic
process for introducing equipment and training staff can
now be outlined and implemented [10,48,52,56]. Finally,
the cost effectiveness of $50 per DALY and cost per life
saved of $1673 compares favourably with several other
interventions against pneumonia [10]. For most coun-
tries however, accurate estimates of cost will be impossi-
ble until there is an improvement in the information on
current oxygen capacities (Table 1).
There are a number of limitations in this review that
deserve mention. Although the search strategy used was
very broad, it may have been preferable to develop spe-
cific search terms for each criteria. This could have
reduced the need for pro-active reference screening and
unpublished report searching that was necessary in this
review and detracted from its systematic nature. In addi-
tion, the absence of articles in foreign languages is pro-
blematic, as non-English speaking countries are so
widely referred to. Future studies should include articles
in other languages. Finally, attempts were made to
update cost data for published reviews of concentrators
[53]. This was done by contacting the manufacturers
directly and would have been valuable in estimating the
current costs of purchasing equipment. However, as
only three of six manufactures replied, a general over-
view instead of a fully updated table was produced.
Conclusions
An oxygen system could be a useful intervention in
combating childhood mortality from pneumonia, with a
possible potential disease burden reduction estimated at
20% (Figure 3). It is now feasible to implement and sus-
tain an oxygen system, even in the most remote regions
of the world. Cost of development is estimated to be
low, although additional improvements of the existing
systems are possible. However, a lack of evidence on
effectiveness and sustainability in different contexts may
hamper the investment potential. Further research on
these issues would be highly valuable.
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with other child health interventions, by referring to the
other reports in this series and particularly to their
expert analysis scores. This should inform decision mak-
ing for investment decisions in future interventions to
tackle pneumonia mortality in the future [1].
Additional material
Additional File 1: contains two supplementary tables:
Supplementary Table S1: Details of the literature search and
inclusion and exclusion criteria. Supplementary Table S2: Questions
used in the Phase II CHNRI process
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